Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report
Open Access
- 17 October 2024
- journal article
- research article
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 5 (12) , 100745
Abstract
No abstract availableKeywords
Funding Information
- Bayer AG
- AstraZeneca
- Pfizer Inc
- Eli Lilly and Company
- Merck Sharp & Dohme Ltd
- Roche
This publication has 15 references indexed in Scilit:
- Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the NetherlandsEuropean Journal of Cancer, 2024
- Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non–small-cell Lung CancerClinical Lung Cancer, 2023
- Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung CancerJournal of Thoracic Oncology, 2023
- Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung CancerJournal of Thoracic Oncology, 2023
- Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patientsEuropean Journal Of Cancer Prevention, 2023
- RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical OutcomeClinical Lung Cancer, 2023
- Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort studyLung Cancer, 2022
- The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLCGenes & Diseases, 2020
- Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancerLung Cancer, 2019
- The UMD TP53 database and website: update and revisionsHuman Mutation, 2005